Which has stronger earnings and valuation, PHAT or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Phathom Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phathom Pharmaceuticals $175.11M 4.27 -$221.25M -$1.28 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is PHAT or RGC more profitable?

Regencell Bioscience has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals -41.34% N/A -20.81% Regencell Bioscience N/A N/A N/A

Does the media favor PHAT or RGC?

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 2 mentions for Regencell Bioscience. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Regencell Bioscience's score of 0.93 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATAI or PHAT?

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 1 mentions for Atai Beckley. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Atai Beckley's score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phathom Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRVI or PHAT?

In the previous week, Trevi Therapeutics had 10 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 13 mentions for Trevi Therapeutics and 3 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Trevi Therapeutics' score of 0.25 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Phathom Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PHAT or BHC?

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 3 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Bausch Health Cos' score of 0.59 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Phathom Pharmaceuticals (PHAT) Competitors

$9.25 -0.03 (-0.32%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$9.40 +0.15 (+1.57%)

As of 08:55 AM Eastern

Compare

PHAT vs. RGC, ATAI, TRVI, PBH, and BHC

Should you buy Phathom Pharmaceuticals stock or one of its competitors? Phathom Pharmaceuticals's main competitors and comparable companies include Regencell Bioscience (RGC), Atai Beckley (ATAI), Trevi Therapeutics (TRVI), Prestige Consumer Healthcare (PBH), and Bausch Health Cos (BHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Phathom Pharmaceuticals compare to Regencell Bioscience?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Phathom Pharmaceuticals currently has a consensus price target of $22.86, suggesting a potential upside of 147.10%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Phathom Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Regencell Bioscience has lower revenue, but higher earnings than Phathom Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.27	-$221.25M	-$1.28	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 2 mentions for Regencell Bioscience. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Regencell Bioscience's score of 0.93 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Regencell Bioscience	N/A	N/A	N/A

Phathom Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

Summary

Phathom Pharmaceuticals beats Regencell Bioscience on 9 of the 13 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 1 mentions for Atai Beckley. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Atai Beckley's score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phathom Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has a net margin of -41.34% compared to Atai Beckley's net margin of -14,938.36%. Phathom Pharmaceuticals' return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Atai Beckley presently has a consensus target price of $10.56, indicating a potential upside of 44.80%. Phathom Pharmaceuticals has a consensus target price of $22.86, indicating a potential upside of 147.10%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Phathom Pharmaceuticals has higher revenue and earnings than Atai Beckley. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	661.02	-$660.05M	-$2.18	N/A
Phathom Pharmaceuticals	$175.11M	4.27	-$221.25M	-$1.28	N/A

Atai Beckley has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats Atai Beckley on 12 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Trevi Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Phathom Pharmaceuticals	$175.11M	4.27	-$221.25M	-$1.28	N/A

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Trevi Therapeutics currently has a consensus price target of $27.08, suggesting a potential upside of 43.75%. Phathom Pharmaceuticals has a consensus price target of $22.86, suggesting a potential upside of 147.10%. Given Phathom Pharmaceuticals' higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Trevi Therapeutics had 10 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 13 mentions for Trevi Therapeutics and 3 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Trevi Therapeutics' score of 0.25 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phathom Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Trevi Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Summary

Trevi Therapeutics beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Prestige Consumer Healthcare (NYSE:PBH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of Prestige Consumer Healthcare shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Prestige Consumer Healthcare has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.27	-$221.25M	-$1.28	N/A
Prestige Consumer Healthcare	$1.10B	2.17	$190.30M	$3.57	14.19

Phathom Pharmaceuticals presently has a consensus target price of $22.86, suggesting a potential upside of 147.10%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 39.65%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Phathom Pharmaceuticals is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Prestige Consumer Healthcare had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 5 mentions for Prestige Consumer Healthcare and 3 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Prestige Consumer Healthcare's score of 0.98 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Phathom Pharmaceuticals' net margin of -41.34%. Prestige Consumer Healthcare's return on equity of 11.39% beat Phathom Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Summary

Prestige Consumer Healthcare beats Phathom Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Bausch Health Cos?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Phathom Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Phathom Pharmaceuticals presently has a consensus target price of $22.86, indicating a potential upside of 147.10%. Bausch Health Cos has a consensus target price of $8.00, indicating a potential upside of 15.36%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Bausch Health Cos has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.27	-$221.25M	-$1.28	N/A
Bausch Health Cos	$10.27B	0.25	$157M	-$2.96	N/A

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 3 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 1.25 beat Bausch Health Cos' score of 0.59 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch Health Cos has a net margin of -10.12% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Bausch Health Cos	-10.12%	-561.95%	6.31%

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats Bausch Health Cos on 10 of the 16 factors compared between the two stocks.

Get Phathom Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAT vs. The Competition

Export

Metric	Phathom Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$775.03M	$11.94B	$7.06B	$13.09B
Dividend Yield	N/A	2.69%	2.56%	10.63%
P/E Ratio	-7.23	782.05	270.26	24.33
Price / Sales	4.27	959.69	680.01	125.40
Price / Cash	N/A	15.16	28.88	38.50
Price / Book	-1.51	10.46	11.19	6.43
Net Income	-$221.25M	$2.81B	$3.46B	$348.18M
7 Day Performance	0.87%	0.39%	0.82%	-0.08%
1 Month Performance	-15.45%	0.66%	2.52%	1.47%
1 Year Performance	-10.89%	8.05%	26.78%	21.05%

Phathom Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAT Phathom Pharmaceuticals	3.334 of 5 stars	$9.25 -0.3%	$22.86 +147.1%	-8.4%	$775.03M	$175.11M	N/A	110	Positive News
RGC Regencell Bioscience	0.2961 of 5 stars	$5.28 -2.4%	N/A	-59.0%	$2.68B	N/A	N/A	10	News Coverage
ATAI Atai Beckley	3.6459 of 5 stars	$7.25 flat	$11.06 +52.5%	+80.0%	$2.67B	$4.09M	N/A	80	Analyst Downgrade Short Interest Decrease
TRVI Trevi Therapeutics	2.6881 of 5 stars	$17.80 -3.8%	$26.75 +50.3%	+152.9%	$2.64B	N/A	N/A	20
PBH Prestige Consumer Healthcare	3.7373 of 5 stars	$52.79 -3.8%	$70.75 +34.0%	-22.0%	$2.60B	$1.09B	14.79	540

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAT) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. RGC, ATAI, TRVI, PBH, and BHC

How does Phathom Pharmaceuticals compare to Regencell Bioscience?

Summary

How does Phathom Pharmaceuticals compare to Atai Beckley?

Summary

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Summary

How does Phathom Pharmaceuticals compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. RGC, ATAI, TRVI, PBH, and BHC

How does Phathom Pharmaceuticals compare to Regencell Bioscience?

Do analysts recommend PHAT or RGC?

Which has stronger earnings and valuation, PHAT or RGC?

Do institutionals and insiders hold more shares of PHAT or RGC?

Does the media favor PHAT or RGC?

Is PHAT or RGC more profitable?

Which has more volatility and risk, PHAT or RGC?

Summary

How does Phathom Pharmaceuticals compare to Atai Beckley?

Does the media favor ATAI or PHAT?

Is ATAI or PHAT more profitable?

Do analysts recommend ATAI or PHAT?

Which has better valuation & earnings, ATAI or PHAT?

Which has more risk and volatility, ATAI or PHAT?

Do institutionals & insiders believe in ATAI or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Which has preferable earnings & valuation, TRVI or PHAT?

Do institutionals & insiders hold more shares of TRVI or PHAT?

Do analysts rate TRVI or PHAT?

Does the media favor TRVI or PHAT?

Which has more volatility and risk, TRVI or PHAT?

Is TRVI or PHAT more profitable?

Summary

How does Phathom Pharmaceuticals compare to Prestige Consumer Healthcare?

Do institutionals and insiders hold more shares of PHAT or PBH?

Which has higher valuation and earnings, PHAT or PBH?

Do analysts recommend PHAT or PBH?

Does the media prefer PHAT or PBH?

Which has more volatility and risk, PHAT or PBH?

Is PHAT or PBH more profitable?

Summary

How does Phathom Pharmaceuticals compare to Bausch Health Cos?

Which has more volatility and risk, PHAT or BHC?

Do analysts prefer PHAT or BHC?

Which has better earnings & valuation, PHAT or BHC?

Does the media prefer PHAT or BHC?

Is PHAT or BHC more profitable?

Do insiders & institutionals believe in PHAT or BHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools